NASDAQ:COLL Collegium Pharmaceutical (COLL) Stock Price, News & Analysis $22.77 0.00 (0.00%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$23.15 +0.38 (+1.67%) As of 05:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Collegium Pharmaceutical Stock (NASDAQ:COLL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get COLL alerts:Sign Up Key Stats Today's Range$22.07▼$22.9350-Day Range$21.84▼$36.7252-Week Range$21.65▼$50.79Volume1.99 million shsAverage Volume900,984 shsMarket Capitalization$741.30 millionP/E Ratio18.36Dividend YieldN/APrice Target$48.50Consensus RatingModerate Buy Company Overview Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing and commercializing medicines for patients with central nervous system disorders. The company’s portfolio includes treatments for pain and attention deficit hyperactivity disorder (ADHD), with an emphasis on products that address unmet patient and healthcare-provider needs. Collegium’s pain portfolio includes Xtampza ER, an extended-release oxycodone product designed with abuse-deterrent properties; Nucynta and Nucynta ER, which contain tapentadol and are used to treat certain types of acute and chronic pain; and Belbuca, a buprenorphine buccal film for the management of chronic pain. These products are marketed primarily in the United States. The company expanded beyond pain management through its acquisition of Ironshore Therapeutics, adding a portfolio of ADHD medicines that includes Jornay PM, Mydayis, Quillivant XR, Quillichew ER, Dyanavel XR and Evekeo ODT. Collegium was founded in 2002 and is headquartered in Stoughton, Massachusetts. It sells its products through commercial and specialty-pharmacy channels and works with healthcare professionals and patients throughout the U.S.AI Generated. May Contain Errors. Read More Collegium Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreCOLL MarketRank™: Collegium Pharmaceutical scored higher than 60% of companies evaluated by MarketBeat, and ranked 327th out of 895 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingCollegium Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialCollegium Pharmaceutical has a consensus price target of $48.50, representing about 113.0% upside from its current price of $22.77.Amount of Analyst CoverageCollegium Pharmaceutical has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Collegium Pharmaceutical's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-27.95% Earnings GrowthEarnings for Collegium Pharmaceutical are expected to decrease by -27.95% in the coming year, from $6.19 to $4.46 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Collegium Pharmaceutical is 18.36, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.95.Price to Earnings Ratio vs. SectorThe P/E ratio of Collegium Pharmaceutical is 18.36, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.51.Price to Book Value per Share RatioCollegium Pharmaceutical has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Collegium Pharmaceutical's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted18.98% of the float of Collegium Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverCollegium Pharmaceutical has a short interest ratio ("days to cover") of 8.08.Change versus previous monthShort interest in Collegium Pharmaceutical has recently decreased by 7.04%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCollegium Pharmaceutical does not currently pay a dividend.Dividend GrowthCollegium Pharmaceutical does not have a long track record of dividend growth. News and Social Media1.1 / 5News Sentiment-0.20 News SentimentCollegium Pharmaceutical has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Collegium Pharmaceutical this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for COLL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Collegium Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Collegium Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by Insiders1.85% of the stock of Collegium Pharmaceutical is held by insiders.Percentage Held by InstitutionsCollegium Pharmaceutical has minimal institutional ownership at this time.Read more about Collegium Pharmaceutical's insider trading history. Receive COLL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. COLL Stock News HeadlinesAnalyzing Ardelyx (NASDAQ:ARDX) & Collegium Pharmaceutical (NASDAQ:COLL)September 20 at 4:28 AM | americanbankingnews.comCollegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15, 2026 | seekingalpha.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.September 21 at 1:00 AM | Banyan Hill Publishing (Ad)Collegium Pharmaceutical (NASDAQ:COLL) Sets New 1-Year Low - Here's What HappenedSeptember 15, 2026 | americanbankingnews.comTruist Financial Cuts Collegium Pharmaceutical (NASDAQ:COLL) Price Target to $49.00September 12, 2026 | americanbankingnews.comCollegium Pharmaceutical (NASDAQ:COLL) Reaches New 1-Year Low on Analyst DowngradeSeptember 11, 2026 | americanbankingnews.comCollegium Pharmaceutical (NASDAQ:COLL) Coverage Initiated at Leerink PartnersSeptember 11, 2026 | americanbankingnews.comLeerink Partners initiates coverage of Collegium Pharmaceutical with outperformSeptember 10, 2026 | msn.comSee More Headlines COLL Stock Analysis - Frequently Asked Questions How have COLL shares performed this year? Collegium Pharmaceutical's stock was trading at $46.30 at the start of the year. Since then, COLL shares have decreased by 50.8% and is now trading at $22.77. How were Collegium Pharmaceutical's earnings last quarter? Collegium Pharmaceutical, Inc. (NASDAQ:COLL) posted its quarterly earnings results on Thursday, August, 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.20. The company's revenue was up 6.3% on a year-over-year basis. Read the conference call transcript. How will Collegium Pharmaceutical's stock buyback program work? Collegium Pharmaceutical's board authorized a stock buyback program on Monday, July 7th 2025, which authorizes the company to buy back $150,000,000 in shares, according to EventVestor. This means that the company could purchase up to 15.4% of its shares through open market purchases. Shares buyback programs are typically an indication that the company's leadership believes its stock is undervalued. When did Collegium Pharmaceutical IPO? Collegium Pharmaceutical (COLL) raised $75 million in an IPO on Wednesday, May 6th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers. Who are Collegium Pharmaceutical's major shareholders? Top institutional investors of Collegium Pharmaceutical include BlackRock Inc. (16.78%), Jupiter Topco LLC (6.60%), Assenagon Asset Management S.A. (0.95%) and Bank of America Corp DE (0.84%). Insiders that own company stock include Joseph Ciaffoni, Colleen Tupper, Shirley R Kuhlmann, Gino Santini, David Dieter, Scott Dreyer, Thomas B Smith, Rita J Balice-Gordon, Garen G Bohlin and John Gordon Freund. View institutional ownership trends. How do I buy shares of Collegium Pharmaceutical? Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Collegium Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Collegium Pharmaceutical investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Arista Networks (ANET), Netflix (NFLX) and CrowdStrike (CRWD). Company Calendar Last Earnings8/06/2026Today9/21/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 COLL's financial health is in the Red zone, according to TradeSmith. COLL has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:COLL CIK1267565 Webwww.collegiumpharma.com Phone(781) 713-3699FaxN/AEmployees423Year Founded2002Price Target and Rating Average Price Target for Collegium Pharmaceutical$48.50 High Price Target$60.00 Low Price Target$43.00 Potential Upside/Downside+113.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$1.24 Trailing P/E Ratio18.36 Forward P/E Ratio3.68 P/E GrowthN/ANet Income$62.87 million Net Margins5.93% Pretax Margin9.61% Return on Equity91.43% Return on Assets15.57% Debt Debt-to-Equity Ratio3.32 Current Ratio1.03 Quick Ratio0.84 Sales & Book Value Annual Sales$808.21 million Price / Sales0.92 Cash Flow$15.18 per share Price / Cash Flow1.50 Book Value$9.54 per share Price / Book2.39Miscellaneous Outstanding Shares32,556,000Free Float31,954,000Market Cap$741.30 million OptionableOptionable Beta0.72 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:COLL) was last updated on 9/21/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Collegium Pharmaceutical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
